Company intelligence / Profile preview
Closed Loop Medicine
- Ownership
- Private
- Employees
- ~51
- Development stage
- Phase 2
Overview
Closed Loop Medicine has demonstrated in a clinical study ("PERSONAL COVIDBP") that its integrated drug + digital solution can improve blood pressure control and minimize side effects by enabling personalized dosing of antihypertensive therapy. The company’s approach leverages real-time data from patients to optimize medication regimens dynamically. Results have been published in the Journal of the American Heart Association.
- Therapeutic areas
- Metabolic DisordersEndocrinologyPsychiatryCardiovascularNeurology
- Modalities
- Small moleculeDeviceDigital therapeutic
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Closed Loop Medicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Closed Loop Medicine.